Adenocarcinoma — Trials

Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

9,697 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,751
Recruiting: 1,519
Ph III recruiting: 167
Growth YoY: +8.6%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,318)

clinicaltrialsPublishedShowing 101–127 of 127 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00565851	Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	active not recruiting	Phase 3	1,052	National Cancer Institute (NCI)NIH	3	Dec 30, 2025	clinicaltrials
NCT04639180	A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation	active not recruiting	Phase 3	687	Jiangsu HengRui Medicine Co., Ltd.